Article
BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
International journal of cancer - 15 Mar 2024
Dinter Lisa, Karitzky Paula C, Schulz Alexander, Wurm Alexander A, Mehnert Marie-Christin, Sergon Mildred, Tunger Antje, Lesche Mathias, Wehner Rebekka, Müller Anja, Käubler Theresa, Niessner Heike, Dahl Andreas, Beissert Stefan, Schmitz Marc, Meier Friedegund, Seliger Barbara, Westphal Dana
Abstract excerpt
About 25% of melanoma harbor activating NRAS mutations, which are associated with aggressive disease therefore requiring a rapid antitumor intervention. However, no efficient targeted therapy options are currently available for patients with NRAS-mutant melanoma. MEK inhibitors (MEKi) appear to display a moderate antitumor activity and also immunological effects in NRAS-mutant melanoma, providing an ideal...
Topics
- Humans
- Melanoma
- Proto-Oncogene Proteins B-raf
- Vemurafenib
- Protein Kinase Inhibitors
- Mitogen-Activated Protein Kinase Kinases
- Mutation
- Drug Resistance, Neoplasm